- Customizing Treatment with PEGASYS® May Improve Chances for Success in Hepatitis C
Patients with chronic hepatitis C who respond quickly to PEGASYS® (peginterferon alfa-2a) and COPEGUS® (ribavirin, USP) may have an excellent chance of achieving treatment success with a shortened course of therapy, according to interim results presented at the 57th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Three-quarters of patients with the difficult-to-treat viral genotypes 1 and 4 who had a rapid viral response (RVR) – defined as undetectable levels - Roche Oral Polymerase Inhibitor R1626 Shows Strong Antiviral Activity in Chronic Hepatitis C Patient
New clinical data on the hepatitis C polymerase inhibitor R1626 – currently in development by Roche – show viral reductions greater than those described for other polymerase inhibitors, according to data presented at the 57th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). These results were achieved in chronic hepatitis C patients infected with the difficult-to-treat genotype 1 virus. - AVI BioPharma Reports Results on Hepatitis C Virus Clinical Trial
AVI BioPharma, Inc. (Nasdaq:AVII) reported results today from the second phase of its multicenter study in patients with chronic active hepatitis C virus (HCV) infection. The second phase of this exploratory trial was designed to assess the safety, tolerability, pharmacokinetics (PK), and viral and clinical response to treatment with AVI’s proprietary NEUGENE® antisense compound, AVI-4065, in HCV patients. - Novelos Therapeutics Enrolls 1St Patient in Hepatitis C Trial with NOV-205
Novelos Therapeutics, Inc. (OTCBB: NVLT), a biotechnology company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the first patient has been enrolled in a hepatitis C trial with NOV-205, the company’s second compound. - Tripep Produces Additional Positive Data for Its Hepatitis C DNA Vaccine Using Inovio's DNA Delivery
Inovio Biomedical Corporation (AMEX:INO) announced today that its partner, Tripep AB of Sweden, has achieved additional positive pre-clinical results showing that its ChronVac-C DNA vaccine combined with Inovio's MedPulser(R) DNA delivery system produced a strong immune response against hepatitis C virus (HCV) in a large animal model.
|